This press release features multimedia. View the full release here: https:\/\/www.businesswire.com\/news\/home\/20231214660611\/en\/<\/a><\/p>\n QPS Netherlands High Resolution Mass Spectrometry Laboratory in Groningen, The Netherlands. (Photo: Business Wire)<\/p>\n<\/div>\n This Sciex quadrupole time-of-flight high-resolution mass spectrometer is dedicated to GLP\/GCP quantitation of oligonucleotide therapeutics and the planned expansion into oligonucleotide metabolite identification in Groningen, The Netherlands.<\/p>\n \u201cQPS is committed to responding to the needs of our clients in Europe by adding an Ultra High-Performance Liquid Chromatography\u2013High-Resolution Mass Spectrometry (UPLC-HRMS) system in the Netherlands to focus on oligonucleotides. This is a natural extension of 20+ years of supporting oligonucleotide drug development using LC-(HR)MS\/MS in our Newark, Delaware, USA facility,\u201d said Zamas Lam, PhD, Global Head of Bioanalytical (Mass Spec) & Preclinical Development, QPS LLC.<\/p>\n \u201cThis increase in capacity and capability comes at a pivotal moment for QPS, as we continue our two-decades-long global effort to support the pharma and biotech industries in developing cutting-edge new therapies to address critical needs in healthcare worldwide. This has become an even higher priority with the explosion of work being done in the nucleic acid therapeutics and protein drug development arena,\u201d said Daniel Schulz-Jander, MSc, PhD, Senior Director of Bioanalysis, QPS Netherlands.<\/p>\n Daniel received his Dipl. Chem. from the University of Kassel in chemistry, his Doctor rerum naturalium from the Technische Universit\u00e4t M\u00fcnchen in environmental chemistry, followed by a post-doctoral fellowship in pesticide metabolism at UC Berkeley. Since then, Daniel\u2019s scientific passion has been in bioanalysis. Starting in biotech at Ligand and Arena Pharmaceuticals, he moved to Medtronic where he built a bioanalytical team specializing in drug in tissue analyses. Since February 2022, Daniel has been the Senior Director of bioanalysis mass spectrometry at QPS Netherlands, where his team supports small and large molecule bioanalysis with LC-MS\/MS as well as ICP\/MS. With this expansion, this group now has all the necessary LC-MS and other chromatographic technology for PK\/PD bioanalysis to support clients in drug discovery and development of gene therapies and protein drug development. This group\u2019s expertise lies in the quantitation of oligonucleotides, peptides, intact proteins, and highly hydrophilic low-molecular-weight metabolite biomarkers by UPLC-HRMS, or by immunoaffinity UPLC-MS\/MS (tandem mass spectrometry), or by hybridization-LC-fluorescence.<\/p>\n ABOUT QPS HOLDINGS, LLC<\/i><\/b><\/p>\n QPS is a GLP\/GCP-compliant contract research organization (CRO) delivering the highest grade of discovery, preclinical, and clinical drug development services. Since 1995, it has rapidly expanded from a tiny bioanalysis shop to a full-service CRO with 1,200+ employees in the US, Europe, India and Asia. Today, it offers expanded pharmaceutical contract R&D services with special expertise in Neuropharmacology, DMPK, Toxicology, Bioanalysis, Translational Medicine, and Clinical Development. Through continual enhancements in capacities and resources, QPS stands tall in its commitment to delivering superior quality, skilled performance and trusted service to its valued customers. For more information, visit <\/i>www.qps.com<\/i><\/a> or email <\/i>info@qps.com<\/i><\/a>.<\/i><\/p>\n View source version on businesswire.com: https:\/\/www.businesswire.com\/news\/home\/20231214660611\/en\/<\/a><\/p>\n![\"QPS](\"https:\/\/mms.businesswire.com\/media\/20231214660611\/en\/1970580\/4\/QPS_Netherlands_HRMS_Laboratory.jpg\")
<\/p>\n<\/p>\n
![\"\"](\"https:\/\/cms.businesswireindia.com\/images\/pixel.gif\"){kind=tracking}
<\/p>\n